M. McKeown

发表

Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors

Wei Zhang, M. McKeown, Daniel L Shaw, 2014, Journal of medicinal chemistry.

Selective inhibition of BET bromodomains

William B. Smith, S. Knapp, M. McKeown, 2010, Nature.

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

R. Young, W. Hahn, K. Anderson, 2011, Cell.

Improving FRET dynamic range with bright green and red fluorescent proteins

Michael Z. Lin, Jesse D. Marshall, R. Tsien, 2012, Nature Methods.

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

Charles Y. Lin, John G Doench, R. Young, 2013, Cancer cell.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Eric Vangrevelinghe, Andrew L. Kung, James E. Bradner, 2011, The Journal of experimental medicine.

Improving the photostability of bright monomeric orange and red fluorescent proteins

Michael Z. Lin, Michael W Davidson, Kristin L. Hazelwood, 2008, Nature Methods.

Therapeutic strategies to inhibit MYC.

M. McKeown, J. Bradner, James E Bradner, 2014, Cold Spring Harbor perspectives in medicine.

Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.

Darren L. Smith, David A. Orlando, M. McKeown, 2017, Cancer discovery.

BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines

A. Look, M. McKeown, J. Bradner, 2014, Leukemia.

Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.

M. McKeown, Xiang Xu, Dennis L. Buckley, 2018, ACS chemical biology.

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

James E. Bradner, Jason S. Carroll, X. Shirley Liu, 2015, Nature.

Super-Enhancer analysis defines novel epigenomic subtypes of non-APL AML including an RARα dependency targetable by SY-1425, a potent and selective RARα agonist AUTHORS and AFFILITATIONS:

David A. Orlando, M. McKeown, M. Guenther, 2017 .

Small-Molecule Inhibition of BRDT for Male Contraception

Julio E. Agno, S. Knapp, M. McKeown, 2012, Cell.

Genetic resistance to JAK 2 enzymatic inhibitors is overcome by HSP 90 inhibition

D. Erdmann, M. McKeown, J. Bradner, 2012 .

Autofluorescent proteins with excitation in the optical window for intravital imaging in mammals.

Michael Z. Lin, Robert E Campbell, Ho-Leung Ng, 2009, Chemistry & biology.

Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia

M. McKeown, C. Fiore, E. di Tomaso, 2018, Haematologica.

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

J. Carulli, M. McKeown, M. Eaton, 2022, Blood advances.

Abstract P1-09-08:BCL2L1(BCL-XL) expression and MYC super-enhancer positivity predict sensitivity to the covalent CDK7 inhibitor SY-1365 in triple negative breast cancer (TNBC) cell lines

David A. Orlando, M. McKeown, E. Olson, 2018 .

Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia

David A. Orlando, M. McKeown, M. Eaton, 2017 .

Abstract 1151: SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors

David A. Orlando, M. McKeown, E. Olson, 2017 .

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

M. McKeown, J. Cortes, D. Steensma, 2017 .